MANAGEMENT

Vaxeal’s highly experienced executive team has an extensive track record in company management, immunotherapy product development and regulatory compliance.

The Board also brings a wealth of diverse corporate and M&A experience.

Mr Peter Nicklin, Executive Chairman

Peter Nicklin has spent 28 years in the healthcare industry. He has extensive international experience with a very broad healthcare perspective including pharmaceuticals, biologics, vaccines, medtech, animal health and healthcare services. Until recently, Peter was Corporate Vice-President and President of Baxter for Europe, Middle East and Africa. In this position he was responsible for all of the company’s various businesses in the region. Before joining Baxter in October of 2006, he was a Board Member of Bayer Healthcare AG, where he served as Vice President for Strategy and Business Development, as well as President of Bayer’s Animal Health Division and was responsible for all of Bayer HealthCare businesses in Asia Pacific. Prior to joining Bayer, he was with Novartis AG, where he led the company’s Western and Central European pharmaceuticals business from 2003 to mid-2005. From 1989 to 2003, he worked at Bristol-Myers Squibb, where he held several international executive management positions in the United Kingdom, Germany, Belgium, Australia, and China.

Peter is a Chartered Accountant and began his career with PriceWaterhouseCoopers in London after earning a bachelor’s degree in finance and law at the University of Lancaster.

Dr Ahmed BOUZIDI, Director and CEO

Ahmed Bouzidi is the founder of Vaxeal. He founded and managed SEDAC-Therapeutics inc., a leading biotech pioneer in peptide-based therapeutic vaccines (exit by Leveraged Buy Out), and Biophysiomics inc. (acquired by Chengdu Kuachang Science & Technology, China).

He is a board member of Vaccines Europe and of the European Biopharmaceutical Enterprises (EBE-biopharma), and is a Senior Associate of the Royal Society of Medicine. He held previously senior advisory positions with Chinese pharmaceutical companies and public institutions, and worked 10 years as senior researcher at the LFB.

He holds a Master degree in Animal Biology (University of Lille, France), a PhD in Cellular Biology, and a MBA in Finance (University of New Hampshire, USA)

Mr Serge GRISARD, Vice-Chairman, EVP Corporate Development

Serge Grisard has more than 20 years experience in Healthcare product development, commercialisation and public private partnerships.

He has been involved in global management in the pharmaceutical and MedTech industry with several companies, including Siemens Medical, Pfizer, Astra-Zeneca, KPMG’s Life Sciences Practice and a range of private or listed start-ups. Serge Grisard has a diversified background, including positions in business development, strategic planning, strategic partnership management, sales and marketing, merger & acquisition, and IPO’s.

Originally involved with aerospace technology with NASA (USA), Serge Grisard holds a Master in aerospace engineering and an MBA from IMD.

Pr Giampietro CORRADIN, CTO

Giampietro Corradin graduated in chemistry at the University of Padua and received his PhD degree in chemistry from the University of California, Santa Barbara. After a post-doctoral position in biochemistry at Dartmouth Medical School, Hanover, New Hampshire, he continued his training in molecular immunology at the National Jewish Hospital, Denver, Colorado. He joined the Institute of Biochemistry of Lausanne in 1979 where he remains an Associate Professor. For the last 15 years, the main focus of his laboratory has been the elucidation of the immunological mechanisms of protection in malaria using well-defined animal models. In addition, development of vaccine candidates have been actively pursued by introducing new and faster approaches for the identification, production and development of novel vaccine candidates.

Dr Jerome KERZERHO, Director R&D

Jerome Kerzerho is a graduate in cellular and molecular biology from the University of Paris VI and holds a PhD degree in immunology and biotechnology from the University Paris IX. During his PhD at the Atomic Energy Commissariat (France), he mainly discovered the tumor antigen MDX, and identified new clinically relevant T-cell epitopes in this antigen and in the SVX protein that constitute two Vaxeal cancer immunotherapy candidates. He then joined the University of Southern California as Research Associate where he honed his skills in the field of immunology and was head of a multidisciplinary team that consisted of clinicians, translational researchers, epidemiologists, statisticians, virologists and immunologists that were collaborating on studies concerning the pathogenesis of HIV and HCV diseases and CMV infections in children and women.